Eli Lilly and Company (LLY)
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it a helping hand. Then came the latest trial data for the Danish company's next-generation obesity drug.
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug.
Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly's Tirzepatide in reducing body weight.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?
Lilly is advancing next-gen obesity drugs like oral orforglipron and retatrutide as competition heats up.
Why Eli Lilly's $1 Billion AI Bet Could Reshape Drug Discovery
As of February 13, 2026, shares of Eli Lilly (NYSE:LLY) were trading at $1,040, just 5.8% below the stock's all-time high.
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off
AI-assisted drug discovery isn't just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age.
Baron Opportunity Fund Q4 2025 Contributors And Detractors
SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. Eli Lilly shares contributed to performance as Zepbound continues to gain share for the treatment of obesity. We decided to exit the Oracle position and book a short-term tax loss, spreading the capital across several of the investments listed above.
What Will Drive Eli Lilly Stock's Next Breakout?
Eli Lilly stock (NYSE: LLY) has been on a tear, surging over 60% in just the last six months. This momentum is part of a broader pattern of explosive growth; the stock has repeatedly rallied more than 30% in two-month windows, with standout gains exceeding 50% in both 2021 and 2025.
LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal
Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.
